| Literature DB >> 35433759 |
Shang Wan1, Yi Wei1, Xin Zhang2, Caiwei Yang1, Fubi Hu3, Bin Song1,4.
Abstract
Objective: Clinical evidence suggests that the risk stratification of portal hypertension (PH) plays a vital role in disease progression and patient outcomes. However, the gold standard for stratifying PH [portal vein pressure (PVP) measurement] is invasive and therefore not suitable for routine clinical practice. This study is aimed to stratify PH and predict patient outcomes using liver or spleen texture features based on computed tomography (CT) images non-invasively.Entities:
Keywords: computed tomography; portal hypertension; risk stratification; survival; texture features
Year: 2022 PMID: 35433759 PMCID: PMC9010529 DOI: 10.3389/fmed.2022.863596
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
FIGURE 1The flowchart of patient enrollment.
FIGURE 2The delineation of the region of interest of the liver (A) and spleen (B) on CT images.
Demographics and clinical characteristics of the study population.
| Variables |
| Low-risk PH | High-risk PH | Statistics |
|
| Age, years | 114 | 48.64 ± 11.45 | 52.04 ± 8.87 | −1.711 | 0.091 |
|
| 1.671 | 0.196 | |||
| Male | 78 | 29 (61.70%) | 49 (73.13%) | ||
| Female | 36 | 18 (38.30%) | 18 (26.87%) | ||
|
| −0.066 | 0.947 | |||
| Post-hepatic cirrhosis | 73 | 32 (68.09%) | 41 (61.19%) | ||
| Alcoholic cirrhosis | 14 | 2 (4.26%) | 12 (17.91%) | ||
| Combined cirrhosis | 12 | 4 (8.51%) | 8 (11.94%) | ||
| Primary biliary cirrhosis | 7 | 3 (6.38%) | 4 (5.97%) | ||
| Others | 8 | 6 (12.77%) | 2 (2.99%) | ||
| −0.253 | 0.8 | ||||
| Child–Pugh class A | 35 | 15 (31.91%) | 20 (29.85%) | ||
| Child–Pugh class B | 61 | 25 (53.19%) | 36 (53.73%) | ||
| Child–Pugh class C | 18 | 7 (14.89%) | 11 (16.42%) | ||
| 114 | 17.00 (15.20, 18.00) | 22.00 (21.00, 27.00) | −8.805 | <0.001 | |
|
| 1.131 | 0.288 | |||
| Absent | 17 | 9 (19.15%) | 8 (11.94%) | ||
| Present | 97 | 38 (80.85%) | 59 (88.06%) | ||
|
| 0.77 | 0.38 | |||
| Absent | 20 | 10 (21.28%) | 10 (14.93%) | ||
| Present | 94 | 37 (78.72%) | 57 (85.07%) | ||
|
| 0.337 | 0.561 | |||
| Absent | 88 | 35 (74.47%) | 53 (79.10%) | ||
| Present | 26 | 12 (25.53%) | 14 (20.90%) | ||
|
| 2.433 | 0.119 | |||
| Absent | 105 | 46 (97.87%) | 59 (88.06%) | ||
| Present | 9 | 1 (2.13%) | 8 (11.94%) | ||
| Total bilirubin | 114 | 21.50 (13.30, 30.72) | 26.30 (16.34, 32.46) | −1.361 | 0.173 |
| Albumin | 114 | 34.40 ± 6.50 | 33.09 ± 6.12 | 1.096 | 0.275 |
| Globulin | 114 | 27.60 (23.68, 31.82) | 26.90(22.62, 32.06) | 0.653 | 0.514 |
| ALT | 114 | 21.00 (13.20, 31.80) | 21.00 (14.00, 43.40) | −0.458 | 0.647 |
| AST | 114 | 32.00 (22.00, 43.80) | 31.00 (21.20, 55.60) | −0.622 | 0.534 |
| INR | 114 | 1.24 (1.15, 1.39) | 1.35 (1.23, 1.48) | −2.331 | 0.02 |
| PLT | 114 | 62.00 (51.20, 89.20) | 63.00 (40.20, 100.40) | 0.636 | 0.525 |
PH, portal hypertension; PVP, portal vein pressure; EVB, esophageal variceal bleeding; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; PLT, platelet count.
Univariate analysis for stratifying portal hypertension.
| Variables | Prediction of high-risk PH | |
| OR (95% CI) |
| |
| log.sigma.3.0.mm.3D_firstorder_RobustMeanAbsoluteDeviation | 0.71 (0.54–0.94) | 0.017 |
| wavelet.LLH_ngtdm_Busyness | 3.74 (1.28–10.9) | 0.016 |
| wavelet.HLL_glrlm_RunLengthNonUniformity | 2.08 (1.1–3.95) | 0.025 |
| wavelet.HLH_glcm_MCC | 0.57 (0.34–0.95) | 0.03 |
| wavelet.LLL_glrlm_RunLengthNonUniformity | 2.1 (1.09–4.05) | |
| INR | 7.76 (1.14–52.88) | 0.036 |
PH, portal hypertension; OR, odds ratio; CI: confidence interval; INR, international normalized ratio.
The performance of texture features and INR for stratifying portal hypertension.
| Variables | AUC (95% CI) | Accuracy | Specificity | Sensitivity | Cutoff |
| log.sigma.3.0.mm.3D_firstorder_RobustMeanAbsoluteDeviation | 0.605 (0.49–0.710) | 0.658 | 0.333 | 0.899 | 0.493 |
| wavelet.LLH_ngtdm_Busyness | 0.72 (0.622–0.817) | 0.746 | 0.681 | 0.791 | 0.517 |
| wavelet.HLL_glrlm_RunLengthNonUniformity | 0.594 (0.509–0.717) | 0.55 | 0.843 | 0.333 | 0.618 |
| wavelet.HLH_glcm_MCC | 0.593 (0.489–0.705) | 0.65 | 0.275 | 0.928 | 0.5 |
| wavelet.LLL_glrlm_RunLengthNonUniformity | 0.604 (0.518–0.726) | 0.592 | 0.588 | 0.594 | 0.553 |
| INR | 0.629 (0.525–0.733) | 0.649 | 0.468 | 0.776 | 0.528 |
AUC, the area under the ROC curve; CI, confidence interval; INR, international normalized ratio.
FIGURE 3Receiver operating characteristic (ROC) analysis of selected texture. features and international normalized ratio (INR) for predicting high-risk portal hypertension (PH). (A) The ROC curve calculated by texture features of log.sigma.3.0.mm.3D_firstorder_RobustMeanAbsoluteDeviation, wavelet.LLH_ngtdm_Busyness, wavelet.HLL_glrlm_RunLengthNonUniformity, wavelet.HLH_glcm_MC, and wavelet.LLL_glrlm_RunLengthNonUniformity. (B) The ROC curve of INR for predicting high-risk PH.
Univariate Cox proportional hazard regression for survival.
| Variables | Survival analysis for PFS | |
| HR (95% CI) |
| |
| log.sigma.3.0.mm.3D_firstorder_RobustMeanAbsoluteDeviation | 0.529 (0.322–0.869) | 0.012 |
| wavelet.LLH_ngtdm_Busyness | 0.727 (0.266–1.991) | 0.535 |
| wavelet.HLL_glrlm_RunLengthNonUniformity | 1.053 (0.671–1.653) | 0.821 |
| wavelet.HLH_glcm_MCC | 1.352 (0.775–2.361) | 0.288 |
| wavelet.LLL_glrlm_RunLengthNonUniformity | 1.03 (0.651–1.63) | 0.9 |
HR, hazard ratio; CI, confidence interval; PFS, progression-free survival.
FIGURE 4Texture features for the evaluation of patient survival. As the picture depicts, only the liver-derived feature of log.sigma.3.0.mm. 3D_firstorder_RobustMeanAbsoluteDeviation could stratify patients with portal hypertension into high- or low-risk group (log-rank test, p < 0.05).
FIGURE 5Representative cases for stratifying portal hypertension (PH) and patients’ survival condition. (A,B) Visualized spleen-derived texture feature of wavelet.LLH_ngtdm_Busyness in high-risk PH patients [portal vein pressure (PVP) ≥ 20 mm Hg] and low-risk PH patients (PVP < 20 mm Hg) respectively. (C,D) Visualized liver-derived texture feature of log.sigma.3.0.mm.3D_firstorder_RobustMeanAbsoluteDeviation in the high-risk patients and low-risk patients, respectively.